Peptide-Based Antiviral Drugs.

Murugan, N Arul et al.·Advances in experimental medicine and biology·2021·Moderate EvidenceReview
RPEP-05631ReviewModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
N=N/A (review)
Participants
N/A (review of antiviral peptide drug landscape)

What This Study Found

60+ FDA-approved peptide drugs with 150+ in clinical trials. Antiviral peptides offer high specificity but face stability and delivery challenges addressable by chemical modification.

Key Numbers

60+ FDA approved; 150+ in clinical trials; since 1920; challenges: serum stability, oral BA, permeability; addressable by chemical modification

How They Did This

Book chapter reviewing antiviral peptide drugs, their mechanisms, advantages, disadvantages, and comparison with small molecules.

Why This Research Matters

New antiviral drugs are always needed. Peptides offer a different approach from traditional small molecules with potentially better specificity.

What This Study Doesn't Tell Us

Review/book chapter. Broad overview rather than deep analysis of specific antiviral peptides. Field is rapidly evolving.

Trust & Context

Original Title:
Peptide-Based Antiviral Drugs.
Published In:
Advances in experimental medicine and biology, 1322, 261-284 (2021)
Database ID:
RPEP-05631

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-05631·https://rethinkpeptides.com/research/RPEP-05631

APA

Murugan, N Arul; Raja, K Muruga Poopathi; Saraswathi, N T. (2021). Peptide-Based Antiviral Drugs.. Advances in experimental medicine and biology, 1322, 261-284. https://doi.org/10.1007/978-981-16-0267-2_10

MLA

Murugan, N Arul, et al. "Peptide-Based Antiviral Drugs.." Advances in experimental medicine and biology, 2021. https://doi.org/10.1007/978-981-16-0267-2_10

RethinkPeptides

RethinkPeptides Research Database. "Peptide-Based Antiviral Drugs." RPEP-05631. Retrieved from https://rethinkpeptides.com/research/murugan-2021-peptidebased-antiviral-drugs

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.